|
|
| (22 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Breast cancer]] |
| {{SI}}
| |
| {{CMG}} {{AE}} {{FZ}}; {{Ammu}}
| |
| | |
| {{SK}} Synonym 1; Synonym 2; Synonym 3
| |
| ==Overview==
| |
| ==Historical Perspective==
| |
| *[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
| |
| *In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
| |
| *In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
| |
| ==Classification==
| |
| *[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
| |
| :*[group1]
| |
| :*[group2]
| |
| :*[group3]
| |
| *Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
| |
| ==Pathophysiology==
| |
| * Lobular carcinoma in situ (LCIS) is a condition in which there is presence of unusual cells in the [[lobule]]s of the [[breast]].<ref name="urlLobular Carcinoma in situ (LCIS) - Breast Cancer - Stanford Cancer Center">{{cite web |url=http://cancer.stanford.edu/breastcancer/lcis.html |title=Lobular Carcinoma in situ (LCIS) - Breast Cancer - Stanford Cancer Center |format= |work= |accessdate=}}</ref>
| |
| * It is usually not considered [[cancer]], but it can indicate an increased risk of future cancer.<ref name="urlLobular carcinoma in situ: Marker for breast cancer risk - MayoClinic.com">{{cite web |url=http://www.mayoclinic.com/health/lobular-carcinoma-in-situ/DS00982 |title=Lobular carcinoma in situ: Marker for breast cancer risk - MayoClinic.com |format= |work= |accessdate=}}</ref><ref name="urlBreast Cancer Treatment - National Cancer Institute">{{cite web |url=http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page6 |title=Breast Cancer Treatment - National Cancer Institute |format= |work= |accessdate=}}</ref><ref name="pmid18562954">{{cite journal |author=Afonso N, Bouwman D |title=Lobular carcinoma in situ |journal=Eur. J. Cancer Prev. |volume=17 |issue=4 |pages=312–6 |year=2008 |month=August |pmid=18562954 |doi=10.1097/CEJ.0b013e3282f75e5d |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00008469-200808000-00004}}</ref>
| |
| *The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
| |
| *The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
| |
| *On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
| |
| *On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
| |
| ==Causes==
| |
| * [Disease name] may be caused by either [cause1], [cause2], or [cause3].
| |
| * [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
| |
| * There are no established causes for [disease name].
| |
| ==Differentiating [disease name] from other Diseases==
| |
| *[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
| |
| :*[Differential dx1]
| |
| :*[Differential dx2]
| |
| :*[Differential dx3]
| |
| ==Epidemiology and Demographics==
| |
| * The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
| |
| * In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
| |
| ===Age===
| |
| *Patients of all age groups may develop [disease name].
| |
| *[Disease name] is more commonly observed among patients aged [age range] years old.
| |
| *[Disease name] is more commonly observed among [elderly patients/young patients/children].
| |
| ===Gender===
| |
| *[Disease name] affects men and women equally.
| |
| *[Gender 1] are more commonly affected with [disease name] than [gender 2].
| |
| * The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
| |
| ===Race===
| |
| *There is no racial predilection for [disease name].
| |
| *[Disease name] usually affects individuals of the [race 1] race.
| |
| *[Race 2] individuals are less likely to develop [disease name].
| |
| ==Risk Factors==
| |
| *Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
| |
| == Natural History, Complications and Prognosis==
| |
| *The majority of patients with [disease name] remain asymptomatic for [duration/years].
| |
| *Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
| |
| *If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
| |
| *Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
| |
| *Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
| |
| == Diagnosis ==
| |
| ===Diagnostic Criteria===
| |
| *The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
| |
| :*[criterion 1]
| |
| :*[criterion 2]
| |
| :*[criterion 3]
| |
| :*[criterion 4]
| |
| === Symptoms ===
| |
| *[Disease name] is usually asymptomatic.
| |
| *Symptoms of [disease name] may include the following:
| |
| :*[symptom 1]
| |
| :*[symptom 2]
| |
| :*[symptom 3]
| |
| :*[symptom 4]
| |
| :*[symptom 5]
| |
| :*[symptom 6]
| |
| === Physical Examination ===
| |
| *Patients with [disease name] usually appear [general appearance].
| |
| *Physical examination may be remarkable for:
| |
| :*[finding 1]
| |
| :*[finding 2]
| |
| :*[finding 3]
| |
| :*[finding 4]
| |
| :*[finding 5]
| |
| :*[finding 6]
| |
| === Laboratory Findings ===
| |
| *There are no specific laboratory findings associated with [disease name].
| |
| *A [positive/negative] [test name] is diagnostic of [disease name].
| |
| *An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
| |
| *Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
| |
| ===Imaging Findings===
| |
| *There are no [imaging study] findings associated with [disease name].
| |
| *[Imaging study 1] is the imaging modality of choice for [disease name].
| |
| *On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
| |
| *[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
| |
| === Other Diagnostic Studies ===
| |
| *[Disease name] may also be diagnosed using [diagnostic study name].
| |
| *Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
| |
| == Treatment ==
| |
| === Medical Therapy ===
| |
| *There is no treatment for [disease name]; the mainstay of therapy is supportive care.
| |
| *The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
| |
| *[Medical therapy 1] acts by [mechanism of action1].
| |
| *Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
| |
| === Surgery ===
| |
| *Surgery is the mainstay of therapy for [disease name].
| |
| *[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
| |
| *[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
| |
| === Prevention ===
| |
| *There are no primary preventive measures available for [disease name].
| |
| *Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
| |
| *Once diagnosed and successfully treated, patients with [disease name] are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].
| |
| ==References==
| |
| {{Reflist|2}}
| |
| [[Category:Oncology]]
| |